Immix Biopharma (IMMX) Depreciation and Depletion (2021 - 2026)
Immix Biopharma (IMMX) posted Depreciation and Depletion of $91577.0 for Q1 2026, up 75.72% sequentially from $52114.0 in Q4 2025, and up 140.03% YoY from $38153.0 in Q1 2025.
Immix Biopharma (IMMX) Depreciation and Depletion (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Depreciation and Depletion for 6 years, with the latest figure at $91577.0 in Q1 2026.
- Quarterly Depreciation and Depletion rose 140.03% year-over-year to $91577.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $299171.0 (up 339.41% YoY) and the FY2025 annual result came in at $245747.0, up 646.02% from the prior year.
- Depreciation and Depletion climbed to $91577.0 in Q1 2026 per IMMX's latest filing, from $52114.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $96986.0 in Q3 2025 and troughed at $383.0 in Q2 2022.
- A 5-year average of $22227.5 and a median of $3076.0 in 2023 frame the typical range for Depreciation and Depletion.
- The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion slumped 38.23% in 2022, then jumped 1679.89% in 2025.
- Over 5 years, Depreciation and Depletion stood at $566.0 in 2022, then surged by 443.46% to $3076.0 in 2023, then soared by 569.8% to $20603.0 in 2024, then surged by 152.94% to $52114.0 in 2025, then surged by 75.72% to $91577.0 in 2026.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $91577.0, $52114.0, and $96986.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 90,993.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90,993.00 |
| Jun 30, 2026 | 90,993.00 |
| Mar 31, 2026 | 91,577.00 |
| Mar 31, 2026 | 91,577.00 |
| Dec 31, 2025 | 52,114.00 |
| Dec 31, 2025 | 52,114.00 |
| Sep 30, 2025 | 96,986.00 |
| Sep 30, 2025 | 96,986.00 |
| Jun 30, 2025 | 58,494.00 |
| Jun 30, 2025 | 58,494.00 |
| Mar 31, 2025 | 38,153.00 |
| Mar 31, 2025 | 38,153.00 |
| Dec 31, 2024 | 20,603.00 |
| Dec 31, 2024 | 20,603.00 |
| Sep 30, 2024 | 5,449.00 |
| Sep 30, 2024 | 5,449.00 |
| Jun 30, 2024 | 3,879.00 |
| Jun 30, 2024 | 3,879.00 |
| Mar 31, 2024 | 3,010.00 |
| Mar 31, 2024 | 3,010.00 |